Background: Atrial fibrillation (AF) increases the risk of stroke, but this risk is not homogenous. Many risk factors contribute to stroke risk however, the evidence for female sex as a risk factor is less wellestablished. Aim: To perform a systematic review and metaanalysis of the available evidence to establish if female sex is a risk factor for stroke/thromboembolism among patients with AF. Methods: A systematic literature search was conducted using Medline. The search term 'atrial fibrillation' was used in combination with 'stroke risk', 'thromboembolism', 'female' and 'gender differences' and returned 735 articles, of which 17 were appraised and included. Females with AF were compared with males with AF for the outcome of stroke/ thromboembolism. Results: Seventeen studies, 5 randomized-controlled trials and 12 prospective observational studies were
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Background: Atrial fibrillation (AF) increases the risk of stroke, but this risk is not homogenous. Many risk factors contribute to stroke risk however, the evidence for female sex as a risk factor is less wellestablished. Aim: To perform a systematic review and metaanalysis of the available evidence to establish if female sex is a risk factor for stroke/thromboembolism among patients with AF. Methods: A systematic literature search was conducted using Medline. The search term 'atrial fibrillation' was used in combination with 'stroke risk', 'thromboembolism', 'female' and 'gender differences' and returned 735 articles, of which 17 were appraised and included. Females with AF were compared with males with AF for the outcome of stroke/ thromboembolism. Results: Seventeen studies, 5 randomized-controlled trials and 12 prospective observational studies were included; 10 demonstrated an increased risk of stroke in women. Meta-analysis of the 17 studies revealed a 1.31-fold (95% confidence intervals (CIs) 1.18-1.46) elevated risk of stroke in women with AF; the risk appearing greatest for women aged 575 years. Only three studies compared entirely anticoagulated populations; stroke rates among these patients varied from 1.2-1.44% perpatient year for men and 2.08-2.43% per-patient year for women. Risk of stroke in women appeared similar regardless of oral anticoagulation therapy [risk ratio (95% CI 1.29 (1.09-1.52) and 1.49 (1.17-1.90) in non-anticogulated vs. anticoagulated/mixed cohorts, respectively). Conclusions: Women with AF are at increased risk of stroke, particularly elderly women. Comprehensive stroke risk assessment, including sex as a risk factor, should be undertaken in all AF patients.
Background
Atrial fibrillation (AF) is an independent risk factor for stroke, increasing this risk 5-fold, 1 however this risk is not homogenous and is dependent on the presence or absence of a number of individual risk factors. 2 The incidence and prevalence of AF varies among men and women. There is a greater incidence of AF in men at all ages, however the prevalence of AF in women aged 575 years is twice that of men due to an average longer lifespan in women. 3 The Rotterdam Study Investigators 4 calculated the lifetime risk of developing AF in women and men aged 555 years was 22.2% and 23.8%, respectively. This variation in incidence and prevalence results in the absolute number of men and women with AF being roughly equal. 3 Numerous factors contribute to an individual's risk of stroke when diagnosed with AF; many are well-established including congestive heart failure, hypertension, advancing age (575 years), diabetes mellitus and a history of stroke or transient ischaemic attack (TIA), 5 which are included in the CHADS 2 stroke risk scoring system. 6 More recent evidence has suggested that other previously 'less-well' validated risk factors, such as vascular disease, age 65-74 years and female gender may also be associated with increased stroke risk among AF patients. 2, 5, 7 These newer 'non-CHADS 2 ' risk factors are incorporated in the CHA 2 DS 2 -VASc score, 7 which is advocated for stroke risk assessment in the European Society of Cardiology (ESC) guidelines 8 and its' recent focused update. 9 Several systematic reviews have examined stroke risk factors in AF patients with sub-group analyses focusing on sex differences in stroke risk. In 2007, the Stroke Risk in AF Working Group identified four clinical features as consistently independent risk factors for stroke in patients with AF, however female gender was not one of these. 5 Conversely, a review carried out by Women's Health published in 2011 concluded that women with AF have a higher thromboembolic stroke risk than men. 10 This review does highlight that women with AF often have a greater number of co-morbidities compared to men with AF, and this may lead to the apparent increase of stroke risk in women. 10 The primary aim of this systematic review and meta-analysis was to examine whether women with AF have an increased risk of stroke compared to men, to quantify the magnitude of this risk, and to provide an updated overview of the available evidence.
Methods

Inclusion criteria
Types of studies
All randomized-controlled trials (RCTs) and prospective observational studies were eligible for inclusion however, case-control studies were excluded. The search was restricted to papers published in English.
Types of participants
The patient population was restricted to those with AF. Studies with male-only populations were excluded; the review compared stroke risk in females AF patients compared with males with AF. Studies focusing primarily on subjects with paroxysmal AF were also excluded, as were studies where the population size was <200, to avoid less reliable results from smaller cohorts. There were no age restrictions. The age and ethnicity of participants was recorded, as was the antithrombotic therapy (oral anticoagulation (OAC), anti-platelet(s) or no treatment) employed.
Types of outcome measures
The primary outcome was stroke or thromboembolism, classified as a composite of any of the following: 'ischaemic, haemorrhagic, or unspecified stroke, TIA and systemic embolism'. Outcome definitions were based on the International Classification of Disease (ICD-10 codes 163-164, G45, 174) as employed within each study. Studies were excluded if a hazard ratio, odds ratio (OR) or relative risk (RR) was not presented or if it was not clear which sex was the exposure sex.
Search methods for identification of studies
A comprehensive structured literature search was performed using MEDLINE for studies published between 1 January 1988 and 18 December 2012 that reported on AF and stroke risk in women compared with men. The search terms included each of the following terms individually and in combination: 'atrial fibrillation', 'thromboembolism', 'stroke risk', 'female' and 'gender differences', returning 735 studies.
Selection of studies
The articles retrieved from the search were firstly screened based on the title and abstract, by one reviewer, to exclude studies that were obviously irrelevant to the review, and checked by a second reviewer. Exclusion criteria were then applied to the remaining articles. The reference lists of all retrieved full papers were examined to identify any other potentially relevant articles and contact with the authors of relevant papers highlighted any other published articles pertinent to the review (n = 8).
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Based on the title and abstract 699 articles were excluded ( Figure 1 ). Full papers for the remaining 36 studies were retrieved and reviewed by 1 reviewer and 27 were excluded; 15 were duplicates, 5 lacked information on female sex and 1 had a population size 4200. Two studies did not report a hazard ratio, OR or RR or in two the exposure sex was not apparent. One case-control study and one study comparing female AF patients with female non-AF patients were also eliminated.
Data extraction
The following data were extracted from each relevant paper by one reviewer (AW) and checked by other reviewers (TFO/DAL): type of study, number and age of participants, percentage female/male, treatment regime employed, number of stroke/ thromboembolic events separately for women/men, point estimate associated with female sex in predicting stroke/thromboembolism.
Pooled risk ratios and 95% confidence intervals (CIs) were estimated using DerSimonian and Laird random-effects models applied to account for within-and between study variations 12 using Review Manager 5.1 software. Where available multivariate risk ratios (95% CI) were entered into the meta-analyses. Study heterogeneity was assessed by the I 2 statistic with an I 2 5 50% considered as evidence of substantial heterogeneity.
11 Sub-group analyses were undertaken to examine the effects of patients within the cohort receiving OAC: grouped as non-anticoagulated and anticoagulated (which included mixed cohorts where some patients received OAC while others did not). In addition, those studies that reported risk ratios stratified by age groups were also meta-analysed to examine the risk of stroke in women aged 75 years and older.
Results
Searches identified 17 relevant studies, 5 RCTs and 12 prospective observational studies. The number of participants ranged from n = 276 13 to >90 000 14 and were generally elderly (565 years). Population age varied from a mean age of 62 15 to 83 years. 16 Three studies [16] [17] [18] consisted of entirely anticoagulated cohorts however medications differed; two 16, 17 employed therapeutic dose-adjusted warfarin, whereas one 16 compared warfarin with ximelagatran. Four studies 13, 15, 19, 20 consisted of mixed cohorts of anticoagulated/non-anticoagulated patients, while the remaining 10 studies 1, 14, 21, [22] [23] [24] [25] [26] [27] [28] were not anticoagulated.
The length of follow-up varied greatly across studies and was not reported in two. 16, 19 The Euro Heart study 20 was the shortest at 12 months, while the Danish National Registry cohort was the longest at 12 years. 21 Reported outcomes differed across studies. In two, 22, 23 the outcome was limited exclusively to ischaemic stroke, eight 1, 13, 14, 19, 20, [24] [25] [26] used a broader outcome of 'stroke', which included ischaemic, haemorrhagic and unspecified strokes, with the remaining seven studies [15] [16] [17] [18] 21, 27 ,28 using a combined outcome of stroke/TIA and thromboembolism.
Ten studies 1, 13, 14, 17, [19] [20] [21] [22] 25, 27 reported an independent increased risk of stroke among female AF patients, although one 21 only reported an increased risk among women aged 575 years, while four studies reported an equivocal estimation 15, 18, 23, 26 after multivariate adjustments. Three studies reported only univariate risk estimates. 16, 24, 28 A meta-analysis of all 17 included studies 1, [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] investigating the relationship between gender and stroke risk revealed an overall risk ratio (95% CIs) of 1.31 (1.18-1.46) (Figure 2 ). For the Olesen study 28 the 1-year data were used in the metaanalysis. Risk ratios and 95% CIs could not be calculated for two studies; 21, 22 the SPAF 1 study 22 did not report 95% CIs and the Mikkelsen study 21 reported stroke rates in women stratified by age groups rather than an overall risk for females in their cohort. The I 2 -statistic of 72% revealed considerable heterogeneity between the studies. Duplicates (n=15); lacking information on female gender (n=5); population too small (n=1); no quantification of risk (n=2); exposure sex not apparent (n=2); case-control studies (n=1); non-AF population (n=1) Figure 1 . PRISMA diagram illustrating the selection process for the studies for inclusion in the review.
A sub-group analysis conducted on the three studies 14, 21, 27 that reported the risk of stroke in women stratified by age group, demonstrated an elevated risk of stroke among women aged 75 years or older, risk ratio (95% CI) 1.28 (1.15-1.43); however, there was significant heterogeneity between the studies (I 2 = 79%).
Non-anticoagulated populations. Results from
RCTs of non-anticoagulated AF cohorts were inconclusive. [22] [23] [24] [25] The European Atrial Fibrillation Trial (EAFT) 25 and the Stroke Prevention in Atrial Fibrillation (SPAF) I study 22 both concluded that women were at increased risk of stroke compared to men after adjustment (HR 1.5 (95% CI 1.0-2.4) and HR 1.6 (95% CI not reported), respectively). It should be noted that the population used in the SPAF I study was treated with aspirin alone or aspirin in combination with low-dose warfarin (sub-therapeutic INR >1.5). 22 The Atrial Fibrillation Investigators (AFI) 24 and Birmingham Atrial Fibrillation Treatment of the Aged (BAFTA) study 23 found no significant increased risk of stroke in women ( Table 1) .
The majority of prospective observational studies in non-anticoagulated AF cohorts demonstrated an increased risk of thromboembolism in women. 1, 14, 21, 28 One analysis from the General Practice Research Database in the UK 26 found no significant increased risk after adjustments were made for a large number of co-factors associated with stroke (OR for women 0.95, 95% CI 0.84-1.06).
The older cohort studies, Framingham 1 and the Anticoagulation and Risk factors In Atrial fibrillation (ATRIA) study, 27 both demonstrated a greater risk of stroke among women, with a HR 1.92 (95% CI 1.20-3.07) and RR 1.62 (95% CI 1.3-1.9), respectively. The large Swedish AF cohort 14 and Danish National Registry, 21 also highlighted that female gender was an independent risk factor for stroke in AF patients with HRs of 1.18 (95% CI 1.13-1.25) 14 and particularly among those aged 75 years and older with HRs of 1.23 (95% CI 1.17-1.30) and 1.10 (95% CI 1.05-1.15), respectively, even after adjustment for a large number of co-factors.
In the Danish National Registry cohort 21 when age was categorized into <65, 65-74 and 575, women aged 65-74 (HR 0.98, 95% CI 0.90-1.07) were not at increased risk of stroke compared to men and among those aged <65 years (HR 0.86, 95% CI 0.76-0.98) there was evidence that women were at lower risk of stroke compared to men (Table 1) .
A meta-analysis of the 10 studies 1,14,21-28 which examined the risk of stroke in females among cohorts not receiving OAC revealed an overall risk ratio (95% CIs) of 1.29 (1.09-1.52). Again the risk ratio could not be calculated for two studies 21, 22 and the I 2 -statistic of 78% revealed considerable heterogeneity between the studies.
Anticoagulated
and non-anticoagulated populations-mixed. Among observational studies with a mixture of anticoagulated patients and those receiving no antithrombotic therapy there was 19 also demonstrated an increased risk of stroke for women after multivariate adjustment (HR 1.14, 95% CI 1.07-1.22).
Conversely only one study 15 did not observe a higher stroke risk in women but only seven participants were treated with warfarin while the remainder received aspirin (Table 2 ).
Anticoagulated population. The secondary analysis of the Stroke Prevention using Oral Thrombin Inhibition in Atrial Fibrillation (SPORTIF) study data 18 was the only RCT using an entirely anticoagulated population. Univariate analysis suggested that females were at increased stroke risk but this risk became non-significant after adjustment for age, previous stroke/TIA, coronary artery disease and smoking. 18 Two observational studies 16, 17 of anticoagulated populations found opposing results: one reported that female sex independently doubled the risk of stroke 17 while the other, 16 focusing on very elderly patients (mean age 83 years) found no increased risk of stroke in women with AF (Table 3) .
A meta-analysis was also conducted on the seven studies 13, [15] [16] [17] [18] [19] [20] which looked at the risk of stroke in females among exclusively anticoagulated cohorts and mixed cohorts where some received OAC while others did not. The overall risk ratio (95% CI) for these seven studies was of 1.49 (1.17-1.90) but again there was evidence of considerable heterogeneity between the studies (I 2 = 66%).
Discussion
This systematic review demonstrates that women with AF are at an increased risk of stroke compared with men with AF, primarily driven by a higher risk among women aged 75 years or older. Given the increasing prevalence of AF with the ageing population, it is paramount that those AF patients at highest risk of stroke are identified and treated appropriately. Thus, all AF patients require a comprehensive assessment of their overall stroke risk incorporating female sex into this assessment. Ten studies 1, 13, 14, 17, [19] [20] [21] [22] 25, 27 reported an increased independent risk of stroke among female AF patients, with four 15, 17, 22, 26 failing to find such an association after multivariate analysis. Three studies only reported univariate risk estimates associated with female gender. 16, 24, 28 The magnitude of this increased risk of stroke among women with AF varied markedly, with point estimates ranging from 1.10 (95% CI 1.05-1.15) 19 to 2.6 (95% CI 1.3-5.5), 13 but the meta-analysis of the 17 included studies revealed an overall 1.31-fold (95% CIs 1.18-1.46) increased risk of stroke in women. However, considerable heterogeneity was evident between the studies: of note the age of participants (greater risk in those aged 575 years); definition of stroke employed (all strokes, 1, 13, 14, 19, 20, [24] [25] [26] ischaemic stroke, 22, 23 or stroke/TIA/thromboembolism; [15] [16] [17] [18] 21, 27, 28 and the differences in length of follow-up and the use of OAC in some 13, [15] [16] [17] [18] [19] [20] but not the majority 1, 14, [21] [22] [23] [24] [25] [26] [27] [28] of studies which will likely affect the stroke event rate.
The AFI meta-analysis of five RCTs found a 20% higher risk of stroke in women compared with men; however, this analysis did not adjust for comorbidities associated with stroke. 24 Greater risk of stroke among females was observed in several earlier prospective observational studies, 1, 13, 20, 27 approximately doubling stroke risk. However these studies were significantly smaller than more recently published cohort studies 14, 19, 21, 26, 28 and the risk factors adjusted for in multivariate analyses only included those in the CHADS 2 score.
More recently published prospective observational studies conducted in this area are noteworthy due to their large AF cohorts, 14, 19, 21 with greater numbers of outcome events allowing more reliable risk estimations to be calculated. The Swedish AF Cohort 14 reported >7000 thromboembolic events in a non-anticoagulated population, with the Danish National Registry 21 observing >12 000 thromboembolic events. These studies also adjust for a large number of possible confounding factors in their multivariate analyses, 14, 21 confirming the independent risk of stroke in female AF patients. The Danish National Registry followed up patients for 12 years adding weight to the reliability of the results of this study over time. 21 In this study an independent increased risk of stroke was observed for patients aged 575 years, however there was no difference in stroke risk for women and men aged 65-74 years and some evidence that women aged <65 years have a lower risk of stroke compared to similarly aged men, which is reflected in the focused update of the ESC guidelines. 9 The sub-group analysis of the three studies 14, 21, 27 that reported stroke risk in women stratified by age demonstrated a 1.28-fold increased risk for women aged 75 years or older but there was evidence of significant heterogeneity between the studies. However, as these large cohort studies were register-based only, their results may be confounded by lifestyle factors that could have influenced stroke risk (e.g. smoking, alcohol, physical 14 and Danish Registry 21 in that it was formed of a mixed cohort where some patients were treated with warfarin and others received no anticoagulation therapy. However it should be noted that the warfarin use and anticoagulation control was generally comparable between the sexes.
The prospective observational study with a very elderly anticoagulated population was the only one of its kind and did not report a multivariate risk estimate, 16 suggesting that more research regarding stroke risk in very elderly women with AF is required.
The underlying cause for this perceived increased risk of stroke in women with AF compared with men is still uncertain. Women with AF tend to be older with more co-morbidities, 1, 18, 20, 29 especially a greater prevalence of hypertension 30 than men, however the larger prospective cohort studies have adjusted for many co-factors and the higher risk of stroke among women remains. A number of other possible mechanisms have been postulated that may explain the sex differences of stroke risk in AF patients. 31 It has been suggested that women with AF demonstrate increased thrombogenicity as a result of hormonal differences or other pro-coagulant qualities including raised markers of endothelial dysfunction and prothrombotic factors. 31, 32 In particular there is a link between von-Willebrand factor in women with AF, and these elevated levels of vonWillebrand factor in women may lead to an increase risk of stroke. 33 Hormone replacement therapy (HRT) has also been considered to be associated with the increased risk of stroke seen in females with AF. Three studies included in this review also examined HRT in relation to thromboembolic risk, 18, 22, 27 producing conflicting outcomes. The SPORTIF study 18 attempted to investigate this suspected relationship between HRT and stroke but due to small number of patients receiving the therapy the results were inconclusive. The SPAF trials 22 concluded that HRT was associated with higher rates of ischaemic stroke in women with AF (RR 3.2 P = 0.007). In contrast, in the ATRIA study 27 the use of oral oestrogen therapy did not lead to an increase risk of thromboembolism. Due to the limited number of studies and patients involved, no concrete conclusions can be drawn regarding HRT and thromboembolic risk in women with AF at this time.
Renal dysfunction may be a contributing factor to the greater risk of stroke and death in females as observed recently in a Chinese AF cohort. 34 In this study, renal dysfunction was a significant risk factor for stroke and death in both sexes, however, the risk was almost five times greater in women compared to men. 34 The relationship between renal dysfunction and stroke risk requires investigation in other AF cohorts, especially in females.
Of note, this systematic review includes data from both anticoagulated and non-anticoagulated cohorts of AF patients and both sub-group meta-analyses (non-anti-coagulated and mixed or anticoagulated cohorts) demonstrate a significantly increased risk of stroke for women. Previously it was thought that perhaps women were undertreated with OAC as a result of a suspected increase risk of bleeding. However, a previous review found that women were not more likely to experience a major bleed while taking warfarin and that women demonstrated a greater reduction in thromboembolic risk when receiving OAC than men. 30 This finding is supported somewhat by the recent findings from the EPICA study 16 that found that elderly men with AF had a higher rate of bleeding complications than women when treated with OAC. 16 Given that cohorts of patients treated with OAC therapy still exhibit the same trend of increased stroke risk in women, it is reasonable to conclude that the increased risk of stroke is not a result of women being undertreated. [17] [18] [19] [20] Conversely, Sullivan et al. 35 postulate that the gender-related differences of stroke risk in anticoagulated AF patients could be related to the time spent in the therapeutic range (TTR) for an INR of 2-3. 35 Their data from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study concluded that women with AF experience more ischaemic strokes as a result of poor coagulation control and lower time in TTR. 35 Thus, women with AF may benefit from new anticoagulation agents (thus avoiding the problems with low TTR) or could respond to a more aggressive and tightly controlled anticoagulation therapy regimen. 35 An area of future research in this field could incorporate investigation into the underlying cause of increased propensity to thromboembolism in women with AF. Additional scrutiny of anticoagulated female AF patients may be necessary to establish if the perceived increase in thrombogenicity is a direct result of poor anticoagulation therapy. Preliminary research has indicated that the new oral anticoagulants are similar, or superior to warfarin in the prevention of stroke, irrespective of gender. 36, 37 In the Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) study women derived a statistically significant increased benefit from dabigatran over warfarin. 36, 37 However, current research investigating the relationship between new generation oral anticoagulants and gender is limited.
Limitations. It is possible that our inclusion criteria excluding foreign language papers and cohorts of <200 participants could have led to a selection bias by excluding smaller studies and those with negative results although the funnel plot ( Figure 3 ) demonstrates symmetry suggesting that bias is unlikely. The meta-analyses demonstrated significant heterogeneity between the studies highlighting the differences in the endpoints employed, differing follow-up periods, clinical and methodological differences and other confounding factors, which should be taken into consideration when interpreting the findings.
Conclusions
Women with AF are at increased risk of stroke, particularly elderly women. Comprehensive stroke risk assessment, including female sex as a risk factor, should be undertaken in all AF patients to inform decisions on thromboprophylaxis. This would go some way to reduce the risk and burden of stroke in AF.
